Sun et al., reported that hUMSC-EXOs exerts therapeutic effects on T2DM by significantly improving hyperglycemia and enhancing insulin sensitivity, mainly through the activation of IRS-1 and AKT, as well as repressing the release of proinflammatory cytokines [27]. Here, AKT1 is linked to type 2 diabetes mellitus.